Which has stronger valuation & earnings, NVS or AZN?

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.39 $13.98B $6.98 22.07 Astrazeneca $58.74B 4.54 $10.23B $6.66 25.80

Is NVS or AZN more profitable?

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Astrazeneca 17.19% 30.86% 12.68%

Does the media favor NVS or AZN?

In the previous week, Astrazeneca had 29 more articles in the media than Novartis. MarketBeat recorded 37 mentions for Astrazeneca and 8 mentions for Novartis. Novartis' average media sentiment score of 0.76 beat Astrazeneca's score of 0.29 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Astrazeneca 17 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 8 Negative mention(s) 4 Very Negative mention(s) Neutral

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media refer more to NVS or NVO?

In the previous week, Novo Nordisk A/S had 20 more articles in the media than Novartis. MarketBeat recorded 28 mentions for Novo Nordisk A/S and 8 mentions for Novartis. Novartis' average media sentiment score of 0.76 beat Novo Nordisk A/S's score of 0.74 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Novo Nordisk A/S 17 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NVS or GSK?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.39 $13.98B $6.98 22.07 GSK $43.07B 2.48 $7.54B $3.85 13.71

Is NVS or GSK more profitable?

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% GSK 17.82% 44.28% 11.49%

Does the media favor NVS or GSK?

In the previous week, Novartis had 2 more articles in the media than GSK. MarketBeat recorded 8 mentions for Novartis and 6 mentions for GSK. Novartis' average media sentiment score of 0.76 beat GSK's score of 0.13 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive GSK 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, NVS or SNY?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.39 $13.98B $6.98 22.07 Sanofi $49.35B 2.14 $8.84B $3.58 12.15

Is NVS or SNY more profitable?

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Sanofi 16.95% 13.39% 7.58%

Does the media refer more to NVS or SNY?

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 10 mentions for Sanofi and 8 mentions for Novartis. Novartis' average media sentiment score of 0.76 beat Sanofi's score of 0.54 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Sanofi 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, NVS or ARGX?

Novartis has higher revenue and earnings than argenex. Novartis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novartis $54.53B 5.39 $13.98B $6.98 22.07 argenex $4.25B 12.85 $1.29B $22.46 39.07

Is NVS or ARGX more profitable?

argenex has a net margin of 31.31% compared to Novartis' net margin of 24.87%. argenex's return on equity of 44.37% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% argenex 31.31% 44.37% 37.55%

Does the media prefer NVS or ARGX?

In the previous week, Novartis had 3 more articles in the media than argenex. MarketBeat recorded 8 mentions for Novartis and 5 mentions for argenex. argenex's average media sentiment score of 0.92 beat Novartis' score of 0.76 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive argenex 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novartis (NVS) Competitors

$154.06 -0.56 (-0.36%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$154.04 -0.02 (-0.01%)

As of 07/10/2026 07:16 PM Eastern

Compare

NVS vs. AZN, NVO, GSK, SNY, and ARGX

Should you buy Novartis stock or one of its competitors? MarketBeat compares Novartis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novartis include Astrazeneca (AZN), Novo Nordisk A/S (NVO), GSK (GSK), Sanofi (SNY), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Novartis compare to Astrazeneca?

Novartis (NYSE:NVS) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Novartis has higher earnings, but lower revenue than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.39	$13.98B	$6.98	22.07
Astrazeneca	$58.74B	4.54	$10.23B	$6.66	25.80

Novartis has a net margin of 24.87% compared to Astrazeneca's net margin of 17.19%. Novartis' return on equity of 38.82% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Astrazeneca	17.19%	30.86%	12.68%

13.1% of Novartis shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Novartis pays out 44.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis currently has a consensus price target of $141.20, suggesting a potential downside of 8.35%. Astrazeneca has a consensus price target of $211.00, suggesting a potential upside of 22.78%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts clearly believe Astrazeneca is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, Astrazeneca had 29 more articles in the media than Novartis. MarketBeat recorded 37 mentions for Astrazeneca and 8 mentions for Novartis. Novartis' average media sentiment score of 0.76 beat Astrazeneca's score of 0.29 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Astrazeneca	17 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	8 Negative mention(s)	4 Very Negative mention(s)	Neutral

Summary

Novartis beats Astrazeneca on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to Novo Nordisk A/S?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

13.1% of Novartis shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Novo Nordisk A/S had 20 more articles in the media than Novartis. MarketBeat recorded 28 mentions for Novo Nordisk A/S and 8 mentions for Novartis. Novartis' average media sentiment score of 0.76 beat Novo Nordisk A/S's score of 0.74 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Novo Nordisk A/S	17 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.5%. Novartis pays out 44.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novartis currently has a consensus price target of $141.20, indicating a potential downside of 8.35%. Novo Nordisk A/S has a consensus price target of $65.56, indicating a potential upside of 32.48%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.39	$13.98B	$6.98	22.07
Novo Nordisk A/S	$46.80B	4.72	$15.51B	$4.26	11.62

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novartis compare to GSK?

Novartis (NYSE:NVS) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Novartis had 2 more articles in the media than GSK. MarketBeat recorded 8 mentions for Novartis and 6 mentions for GSK. Novartis' average media sentiment score of 0.76 beat GSK's score of 0.13 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.1% of Novartis shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.39	$13.98B	$6.98	22.07
GSK	$43.07B	2.48	$7.54B	$3.85	13.71

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.4%. Novartis pays out 44.1% of its earnings in the form of a dividend. GSK pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
GSK	17.82%	44.28%	11.49%

Novartis presently has a consensus price target of $141.20, suggesting a potential downside of 8.35%. GSK has a consensus price target of $53.00, suggesting a potential upside of 0.43%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

Summary

Novartis beats GSK on 13 of the 18 factors compared between the two stocks.

How does Novartis compare to Sanofi?

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Sanofi	16.95%	13.39%	7.58%

Novartis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Novartis pays out 44.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.39	$13.98B	$6.98	22.07
Sanofi	$49.35B	2.14	$8.84B	$3.58	12.15

In the previous week, Sanofi had 2 more articles in the media than Novartis. MarketBeat recorded 10 mentions for Sanofi and 8 mentions for Novartis. Novartis' average media sentiment score of 0.76 beat Sanofi's score of 0.54 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sanofi	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Novartis currently has a consensus target price of $141.20, suggesting a potential downside of 8.35%. Sanofi has a consensus target price of $49.50, suggesting a potential upside of 13.79%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novartis compare to argenex?

Novartis (NYSE:NVS) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

13.1% of Novartis shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novartis has higher revenue and earnings than argenex. Novartis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.39	$13.98B	$6.98	22.07
argenex	$4.25B	12.85	$1.29B	$22.46	39.07

In the previous week, Novartis had 3 more articles in the media than argenex. MarketBeat recorded 8 mentions for Novartis and 5 mentions for argenex. argenex's average media sentiment score of 0.92 beat Novartis' score of 0.76 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
argenex	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Novartis presently has a consensus price target of $141.20, indicating a potential downside of 8.35%. argenex has a consensus price target of $1,037.61, indicating a potential upside of 18.23%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has a net margin of 31.31% compared to Novartis' net margin of 24.87%. argenex's return on equity of 44.37% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
argenex	31.31%	44.37%	37.55%

Summary

argenex beats Novartis on 13 of the 16 factors compared between the two stocks.

Get Novartis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVS vs. The Competition

Export

Metric	Novartis	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$293.95B	$329.81B	$7.08B	$23.47B
Dividend Yield	2.00%	2.69%	2.68%	4.02%
P/E Ratio	22.07	29.70	27.42	31.38
Price / Sales	5.39	5.39	527.95	20.36
Price / Cash	14.34	14.06	48.47	25.09
Price / Book	6.99	8.37	10.88	4.77
Net Income	$13.98B	$11.61B	$3.59B	$1.07B
7 Day Performance	-3.60%	-2.39%	-0.26%	-0.50%
1 Month Performance	0.68%	5.78%	4.55%	0.06%
1 Year Performance	27.40%	27.26%	29.86%	17.02%

Novartis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVS Novartis	2.4957 of 5 stars	$154.06 -0.4%	$141.20 -8.3%	+27.4%	$293.95B	$54.53B	22.07	75,267
AZN Astrazeneca	4.7231 of 5 stars	$183.99 -3.0%	$205.33 +11.6%	+20.8%	$285.35B	$58.74B	27.63	96,100	Trending News
NVO Novo Nordisk A/S	4.2043 of 5 stars	$48.69 +1.6%	$65.56 +34.7%	-28.2%	$217.40B	$46.80B	11.43	69,505	Trending News
GSK GSK	2.5946 of 5 stars	$51.36 -2.0%	$53.00 +3.2%	+37.8%	$104.01B	$43.07B	13.35	66,841	Dividend Cut Analyst Forecast
SNY Sanofi	4.2478 of 5 stars	$41.63 -2.4%	$51.00 +22.5%	-10.5%	$100.93B	$49.35B	11.63	74,846	News Coverage Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVS) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Competitors

NVS vs. AZN, NVO, GSK, SNY, and ARGX

How does Novartis compare to Astrazeneca?

Summary

How does Novartis compare to Novo Nordisk A/S?

Summary

How does Novartis compare to GSK?

Summary

How does Novartis compare to Sanofi?

Summary

How does Novartis compare to argenex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novartis (NVS) Competitors

NVS vs. AZN, NVO, GSK, SNY, and ARGX

How does Novartis compare to Astrazeneca?

Which has stronger valuation & earnings, NVS or AZN?

Is NVS or AZN more profitable?

Do insiders & institutionals believe in NVS or AZN?

Is NVS or AZN a better dividend stock?

Do analysts recommend NVS or AZN?

Which has more risk and volatility, NVS or AZN?

Does the media favor NVS or AZN?

Summary

How does Novartis compare to Novo Nordisk A/S?

Do insiders and institutionals have more ownership in NVS or NVO?

Does the media refer more to NVS or NVO?

Which has more volatility and risk, NVS or NVO?

Is NVS or NVO a better dividend stock?

Is NVS or NVO more profitable?

Do analysts recommend NVS or NVO?

Which has higher earnings and valuation, NVS or NVO?

Summary

How does Novartis compare to GSK?

Which has more volatility and risk, NVS or GSK?

Does the media favor NVS or GSK?

Do institutionals and insiders believe in NVS or GSK?

Which has higher valuation & earnings, NVS or GSK?

Is NVS or GSK a better dividend stock?

Is NVS or GSK more profitable?

Do analysts rate NVS or GSK?

Summary

How does Novartis compare to Sanofi?

Is NVS or SNY more profitable?

Which has more volatility & risk, NVS or SNY?

Do institutionals & insiders have more ownership in NVS or SNY?

Is NVS or SNY a better dividend stock?

Which has higher valuation and earnings, NVS or SNY?

Does the media refer more to NVS or SNY?

Do analysts prefer NVS or SNY?

Summary

How does Novartis compare to argenex?

Do institutionals and insiders believe in NVS or ARGX?

Which has preferable valuation & earnings, NVS or ARGX?

Does the media prefer NVS or ARGX?

Which has more volatility & risk, NVS or ARGX?

Do analysts recommend NVS or ARGX?

Is NVS or ARGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVS vs. The Competition

Novartis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools